San Diego Union-Tribune

COVID THERAPY TESTED ON FETAL TISSUE

Cells’ use may raise concerns among conservati­ves

- BY APOORVA MANDAVILLI & NATHALIA HOLT Mandavilli and Holt write for The New York Times.

When the Trump administra­tion suspended federal funding in 2019 for most new scientific research projects involving fetal tissue derived from abortions, officials argued that whatever the scientific benefits, there was a pressing moral imperative to find alternativ­e research methods.

“Promoting the dignity of human life from conception to natural death is one of the very top priorities of President Trump’s administra­tion,” the Department of Health and Human Services said in a statement released at the time.

Yet the treatment for COVID-19 received by Donald Trump — a combinatio­n of monoclonal antibodies he described as a “cure” in a celebrator­y video posted on Twitter — was developed using human cells derived

from a fetus aborted decades ago.

Remdesivir, an antiviral drug that the president received late last week, was also developed with those cell lines. At least two companies racing to create a vaccine against the coronaviru­s, Moderna and AstraZenec­a, are also relying on the cells. Johnson & Johnson is testing its vaccine in another socalled cell line originally produced from fetal tissue.

As participan­ts in the White House’s Operation

Warp Speed, all three vaccine-makers have received federal funding.

A Trump administra­tion official argued Thursday that the president’s embracing of the treatments was not a contradict­ion. The administra­tion’s policy on fetal tissue research “specifical­ly excluded” cell lines made before June 2019, said the official, who did not wish to be identified because he was not authorized to speak about the matter.

Scientific products made using cell lines that existed before then “would not implicate the administra­tion’s policy on the use of human fetal tissue from elective abortions,” the official said.

Some scientists saw a double standard in the president’s endorsemen­t. “Hypocrisy has never bothered the man, as near as I can tell,” Lawrence Goldstein, a neuroscien­tist at the University of California San Diego who has used fetal tissue in his research, said of Trump.

Dr. Deepak Srivastava, a pediatric cardiologi­st who led the Internatio­nal Society for Stem Cell Research until July, said, “If they oppose this research, they should be willing to not take a drug that was developed using that.”

For decades, fetal tissue from abortions has been crucial to scientific research into treatments for conditions from birth defects to Ebola to cancer. And fetal tissue has been particular­ly important for studying the immune system, a key to designing treatments and vaccines for infectious diseases like COVID-19.

The cells used by most of the companies now trying to find a COVID-19 treatment, called the 293T line, were derived from the kidney tissue of a fetus aborted in the 1970s. A similar cell line, Per.C6, was obtained in 1985 from the retinal cells of an aborted 18-week-old fetus.

The treatment that Trump called a cure for COVID-19 is a combinatio­n of two monoclonal antibodies manufactur­ed by Regeneron. Those antibodies are synthesize­d outside the body and then infused into patients to help fight off the infection.

Regeneron tested the antibodies against virus-like particles created using 293T human cells. The viral particles serve as a proxy for the live coronaviru­s; testing otherwise would require a lab with extremely high biosafety levels. (Eli Lilly, which also is manufactur­ing monoclonal antibodies, is using the same method.)

“293Ts were used in testing the antibodies’ ability to neutralize the virus,” said Alexandra Bowie, a spokespers­on for Regeneron. “They weren’t used in any other way, and fetal tissue was not used in the research.”

Trump’s resounding endorsemen­t of Regeneron may run afoul of some religious groups and conservati­ve leaders who have questioned the cells’ use to find treatments or vaccines for use against the coronaviru­s.

“One concern regarding the ethical assessment of viral vaccine candidates is the potential use of abortion-derived cell lines in the developmen­t, production or testing,” David Prentice, vice president of the Charlotte Lozier Institute, wrote in September.

His analysis identified 13 vaccine candidates for the coronaviru­s that rely on fetal cell lines.

Such research is “not morally responsibl­e,” said Dr. James Sherley, a research scholar at the Charlotte Lozier Institute and director of the adult stem cell company Asymmetrex. “There are alternativ­es — there are lots of ways that don’t require the death of anyone.”

 ?? EVAN VUCCI AP ?? President Donald Trump leaves the hospital after receiving experiment­al treatments for COVID-19.
EVAN VUCCI AP President Donald Trump leaves the hospital after receiving experiment­al treatments for COVID-19.

Newspapers in English

Newspapers from United States